Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded from 64 to 82 Friday.
IBD's unique RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against that of all other stocks.
History reveals that the best stocks typically have an RS Rating north of 80 as they begin their biggest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Vir Biotechnology Stock A Buy?
Vir Biotechnology stock reclaimed its 200-day moving average mid-July and has been etching the right side of a consolidation. Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the biotech stock manages to offer and clear a proper buy point.
The biotech company showed 0% EPS growth in its most recent report. Revenue rose -10%. Look for the next report on or around Aug. 1.
Vir Biotechnology stock earns the No. 279 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
